Sign Out
For treatment of flat Urothelial Cell Carcinoma in Situ of urinary bladder and as adjunctive therapy following Transurethral resection of primary or relapsing superficial noninvasive papillary tumors that are limited to the bladder mucosa (stage Ta or T1).
Intravesical BCG Immunotherapy has been shown to reduce tumor recurrence and prevent progression.
Continue with Google